Agendia Agendia to Distribute Inivata Liquid Biopsy Breast Cancer Test in North America, Europe Agendia will receive co-exclusive rights to distribute Inivata's RaDaR assay for minimal residual disease and relapse detection in Europe and North America. Agendia FLEX Registry Powers Genomics Research on Underrepresented Breast Cancer Patients Premium FLEX will include full transcriptome data paired with 800 data points from 10,000 patients, offering researchers the chance to study diverse patient subsets. Agendia, Paige Partner to Codevelop New Assays Using MammaPrint, BluePrint Signatures The companies aim to create new products enabling faster access to predictive information used in treatment planning for patients with breast cancer. Germany Grants National Reimbursement for Three Additional Breast Cancer Biomarker Tests Myriad Genetics' EndoPredict, Agendia's MammaPrint (distributed in Germany by PathoNext), and Veracyte's Prosigna will now be covered by public insurance. PathoNext to Offer Agendia's Breast Cancer Recurrence Assays in Germany PathoNext will run Agendia's assays in its labs using next-generation sequencing and work with HiSS, Agendia's German distributor, to offer the tests to German patients. Aug 26, 2020 Agendia's MammaPrint Breast Cancer Risk Test Cost-Effective in Multi-Country Analysis Jul 2, 2020 Agendia Settles Allegations of Medicare Fraud for $8.25M Jun 12, 2020 New Data Support Role of Agendia BluePrint Test in Refining Breast Cancer Subtypes Premium May 21, 2019 Agendia, Imegen Ink Distribution Deal for Breast Cancer Tests in Spain, Portugal Dec 19, 2018 Breast Cancer Molecular Tests Included in Recommendations by UK's NICE Dec 10, 2018 SABCS 2018 Features Molecular Diagnostics Research Nov 16, 2018 Agendia Breast Cancer Tests Show Promise for Improved Therapy Prediction Premium Oct 10, 2018 NCCN Update on Breast Cancer Genetic Testing Guidelines Marks Oncotype DX as 'Preferred' Test Sep 18, 2018 Agendia Partners With GeneCast to Launch Tests in China Aug 24, 2018 In Brief This Week: MolecularMD, Agendia, Promega, NRGene, More Jul 25, 2018 Agendia Secures $35M Investment May 24, 2018 Agendia Inks Southeast Asian Marketing Deal for Breast Cancer Tests May 15, 2018 Agendia Breast Cancer Tests Adopted by French Hospital Group May 1, 2018 Aetna, Cigna, UnitedHealthcare to Cover Agendia's MammaPrint Apr 5, 2018 Agendia Moving to Decentralized Testing Model in Europe, Exploring Options for Asia Expansion Premium Mar 21, 2018 Agendia NGS MammaPrint BluePrint Kit Receives CE Mark Feb 7, 2018 UK's NICE Finalizing Updated Breast Cancer Test Guidance Following Stakeholder Comments Premium Dec 19, 2017 Agendia Selects Bluebee as Data Processing Partner for MammaPrint, BluePrint IVD Kit Dec 7, 2017 University Hospitals Leuven Joins Validation Effort for Agendia MammaPrint, BluePrint IVD Kit Dec 5, 2017 Institut Curie Joins Co-Validation Study for Agendia's MammaPrint, BluePrint Breast Cancer Kit Load More Breaking News In Brief This Week: Illumina, Personalis, Proteomedix, and More Ancient DNA Details Population Dynamics Within Andean Tiwanaku Civilization Genomic Data Spanning 2K Years Gives Glimpse of Etruscan Origins, Population Changes People in the News: New Appointments at Hologic, Akoya Biosciences, Caris Life Sciences, More At NSGC, Genetic Counselors Address Race-Based Medicine, Ways to Change New Products Posted to GenomeWeb: Becton Dickinson, Cosmos-ID, OncoDNA, More The Scan US Booster Eligibility Decision The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions. Arizona Bill Before Judge The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction. Additional Genes Wales is rolling out new genetic testing service for cancer patients, according to BBC News. Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.